The PertADO Geneva Trial
Phase 2
Completed
- Conditions
- Pertussis
- Interventions
- Biological: Pertagen® aP + Td-pur®Biological: Boostrix® dTpa
- First Posted Date
- 2016-10-27
- Last Posted Date
- 2017-05-08
- Lead Sponsor
- Siegrist Claire-Anne
- Target Recruit Count
- 60
- Registration Number
- NCT02946190
- Locations
- 🇨🇭
Pediatric clinical trial platform, University Hospitals of Geneva City: Geneva, Geneva, Switzerland
© Copyright 2025. All Rights Reserved by MedPath